ArticleOncotarget
Insights into 4E-BP1 and p53 mediated regulation of accelerated cell senescence.
Article in Oncotarget. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 30 citations in OpenAlex.
- The Impact of Oxidative Stress and AKT Pathway on Cancer Cell Functions and Its Application to Natural Products.Antioxidants (Basel, Switzerland) · 2022Review
- Herb-target virtual screening and network pharmacology for prediction of molecular mechanism of Danggui Beimu Kushen Wan for prostate cancer.Scientific reports · 2021Article
- Inhibition of mTOR Signaling Enhances Maturation of Cardiomyocytes Derived From Human-Induced Pluripotent Stem Cells via p53-Induced Quiescence.Circulation · 2020Article
- Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models.Scientific reports · 2019Article
- The Immortal Senescence.Methods in molecular biology (Clifton, N.J.) · 2017Review
- PKCι depletion initiates mitotic slippage-induced senescence in glioblastoma.Cell cycle (Georgetown, Tex.) · 2015Article
- Crosstalk between Edc4 and mammalian target of rapamycin complex 1 (mTORC1) signaling in mRNA decapping.International journal of molecular sciences · 2014Article
- mTOR kinase-dependent, but raptor-independent regulation of downstream signaling is important for cell cycle exit and myogenic differentiation.Cell cycle (Georgetown, Tex.) · 2014Article
- Mad2 and BubR1 modulates tumourigenesis and paclitaxel response in MKN45 gastric cancer cells.Cell cycle (Georgetown, Tex.) · 2014Article
- Dysregulation of the mTOR pathway in p53-deficient mice.Cancer biology & therapy · 2013Article
- Immunosuppressants in cancer prevention and therapy.Oncoimmunology · 2013Review
- Molecular dynamics of the full-length p53 monomer.Cell cycle (Georgetown, Tex.) · 2013Article
- p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3.Cell cycle (Georgetown, Tex.) · 2012Article
- Rapalogs in cancer prevention: anti-aging or anticancer?Cancer biology & therapy · 2012Review
- Article
- Potential anti-aging agents suppress the level of constitutive mTOR- and DNA damage- signaling.Aging · 2012Article
- Advances in targeting signal transduction pathways.Oncotarget · 2012Review
- Controversial aspects of oncogene-induced senescence.Cell cycle (Georgetown, Tex.) · 2012Review
- NRF2 and p53: Januses in cancer?Oncotarget · 2012Review
- Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression?Aging · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Senescence is a valid tumor suppressive mechanism in cancer. Accelerated cell senescence describes the growth arrested state of cells that have been treated with anti-tumor drugs, such as doxorubicin that induce a DNA damage response. Discodermolide, a microtubule-stabilizing agent, is a potent inducer of accelerated cell senescence. Resistance to discodermolide is mediated via resistance to accelerated cell senescence, and is associated with reduced expression of the mTORC1 substrate, 4E-BP1 and increased expression of p53 [1]. Although the association of p53 with senescence induction is well-characterized, senescence reversion in the presence of high expression of p53 has not been well-documented. Furthermore, studies addressing the role of mTOR signaling in regulating senescence have been limited and recent data implicate a novel, senescence-associated role for 4E-BP1 in crosstalk with the transcription factor p53. This research perspective will address these somewhat contradictory findings and summarize recent research regarding senescence and mTORC1 signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.